Welcome to our dedicated page for Replimune Group SEC filings (Ticker: REPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Replimune Group, Inc. (Nasdaq: REPL) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a clinical stage biotechnology issuer. Replimune, founded in 2015 and headquartered in Woburn, Massachusetts, develops HSV‑1‑based oncolytic immunotherapies through its proprietary RPx platform, with lead programs such as RP1 (vusolimogene oderparepvec) and RP2.
Through this page, users can review Replimune’s current reports on Form 8‑K, which frequently highlight material events including FDA interactions, clinical milestones and financial updates. Recent 8‑K filings have described the FDA’s Complete Response Letter for the RP1 BLA in advanced melanoma, completion of a Type A meeting with the agency, acceptance of a BLA resubmission with a defined PDUFA date, quarterly financial results, and outcomes of the company’s annual meeting of stockholders.
In addition to 8‑Ks, investors can reference Replimune’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q (accessible via the SEC’s EDGAR system) for detailed information on the company’s clinical programs, risk factors, financial condition and cash runway assumptions. The DEF 14A proxy statement provides insight into governance, board structure, executive compensation and matters submitted to shareholder vote, such as director elections and incentive plan amendments.
Stock Titan enhances these filings with AI‑powered summaries that explain the key points of lengthy documents, helping users quickly understand topics like trial design disclosures, regulatory status updates for RP1 and RP2, and the implications of shareholder meeting results. Real‑time updates from EDGAR mean that new Replimune filings, including future 10‑K, 10‑Q, 8‑K and proxy materials, are made available promptly.
For those monitoring insider and equity‑related activity, Replimune’s filings also describe equity incentive plans and inducement grants under Nasdaq Listing Rule 5635(c)(4). Form 4 insider transaction reports, when filed, can be viewed alongside these materials to provide additional context on equity ownership and changes over time.